{
    "root": "422d1ecb-c216-4607-87b2-0be47dfe9bd3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "PLUVICTO",
    "value": "20250328",
    "ingredients": [
        {
            "name": "ACETIC ACID",
            "code": "Q40Q9N063P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15366"
        },
        {
            "name": "SODIUM ACETATE",
            "code": "4550K0SC9B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32954"
        },
        {
            "name": "GENTISIC ACID",
            "code": "VP36V95O3T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "SODIUM ASCORBATE",
            "code": "S033EH8359",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_113451"
        },
        {
            "name": "PENTETIC ACID",
            "code": "7A314HQM0I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_35739"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN",
            "code": "G6UF363ECX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB16778"
        }
    ],
    "indications": {
        "text": "pluvicto indicated treatment adult patients prostate-specific membrane antigen ( psma ) -positive metastatic castration-resistant prostate cancer ( mcrpc ) treated androgen receptor pathway inhibitor ( arpi ) therapy , considered appropriate delay taxane-based chemotherapy , received prior taxane-based chemotherapy .",
        "doid_entities": [
            {
                "text": "prostate cancer (DOID:10283)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10283"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "select patients treatment using locametz \u00ae another approved psma positron emission tomography ( pet ) product based psma expression tumors . ( 2.2 ) recommended : administer 7.4 gbq ( 200 mci ) every 6 weeks 6 doses . ( 2.3 ) dose interruption , reduction , permanent discontinuation may required due . ( 2.4 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "pluvicto injection containing 1,000 mbq/ml ( 27 mci/ml ) lutetium lu 177 vipivotide tetraxetan sterile , preservative-free clear , colorless slightly yellow solution intravenous supplied clear , colorless type glass 30 ml single-dose vial containing 7.4 gbq ( 200 mci ) \u00b1 10 % lutetium lu 177 vipivotide tetraxetan date time ( ndc # 69488-010-61 ) . solution volume vial range 7.5 ml 12.5 ml order provide total 7.4 gbq ( 200 mci ) radioactivity date time . product vial enclosed within lead shielded container ( ndc # 69488-010-61 ) protective shielding placed plastic sealed container . product shipped type package ( ndc # 69488-010-61 ) . shelf life 120 hours ( 5 days ) date time calibration . store 30\u00b0c ( 86\u00b0f ) . freeze . store original package protect ionizing radiation ( lead shielding ) . store pluvicto accordance local federal laws radioactive materials . pluvicto expiration date time stated label . dispose unused medicinal product waste material accordance local federal laws . lutetium-177 pluvicto may prepared using two different sources stable nuclides ( either lutetium-176 ytterbium-176 ) require different waste management . lutetium-177 pluvicto prepared using ytterbium-176 ( \u201c non-carrier added \u201d ) unless otherwise communicated product batch release certificate .",
    "adverseReactions": "none .",
    "indications_original": "PLUVICTO is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy, and\n                  \n                     \n                        are considered appropriate to delay taxane-based chemotherapy, or\n                     \n                        have received prior taxane-based chemotherapy.",
    "contraindications_original": "Select patients for treatment using LOCAMETZ \u00ae or another approved PSMA positron emission tomography (PET) product based on PSMA expression in tumors. ( 2.2 ) Recommended Dosage: Administer 7.4 GBq (200 mCi) every 6 weeks for 6 doses. ( 2.3 ) Dose interruption, reduction, or permanent discontinuation may be required due to adverse reactions. ( 2.4 )",
    "warningsAndPrecautions_original": "PLUVICTO Injection containing 1,000 MBq/mL (27 mCi/mL) of lutetium Lu 177 vipivotide tetraxetan is a sterile, preservative-free and clear, colorless to slightly yellow solution for intravenous use supplied in a clear, colorless Type I glass 30 mL single-dose vial containing 7.4 GBq (200 mCi) \u00b1 10% of lutetium Lu 177 vipivotide tetraxetan at the date and time of administration (NDC# 69488-010-61). The solution volume in the vial can range from 7.5 mL to 12.5 mL in order to provide a total of 7.4 GBq (200 mCi) of radioactivity at the date and time of administration.\n                  The product vial is enclosed within a lead shielded container (NDC# 69488-010-61) for protective shielding and placed in a plastic sealed container. The product is shipped in a type A package (NDC# 69488-010-61).\n                  The shelf life is 120 hours (5 days) from the date and time of calibration.\n                  Store below 30\u00b0C (86\u00b0F). Do not freeze. Store in the original package to protect from ionizing radiation (lead shielding).\n                  Store PLUVICTO in accordance with local and federal laws on radioactive materials.\n                  Do not use PLUVICTO after the expiration date and time which are stated on the label.\n                  Dispose of any unused medicinal product or waste material in accordance with local and federal laws.\n                  Lutetium-177 for PLUVICTO may be prepared using two different sources of stable nuclides (either lutetium-176 or ytterbium-176) that require different waste management. Lutetium-177 for PLUVICTO is prepared using ytterbium-176 (\u201cnon-carrier added\u201d) unless otherwise communicated on the product batch release certificate.",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "PLUVICTO",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15366"
        }
    ]
}